Skip to content
Pharma Observatory a Scientist.com platform

Organization (Industry)

Orchestra BioMed Holdings, Inc.

ClinicalTrials.gov lists Orchestra BioMed Holdings, Inc. as lead sponsor of 25 trials, counting the companies grouped under it.

US Industry Manufacturer CIK 0001814114
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Companies grouped under this page Companies grouped under this page 3 Disease areas Disease areas 5 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 2 Journals published in Journals published in 1 SEC-reported annual financials SEC-reported annual financials 6 Financing and grant events Financing and grant events 34 Climate targets, as filed Climate targets, as filed 1 Workforce and board diversity, as filed Workforce and board diversity, as filed 1 Companies grouped under this page Companies grouped under this page 3 Disease areas Disease areas 5 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 2 Journals published in Journals published in 1 SEC-reported annual financials SEC-reported annual financials 6 Financing and grant events Financing and grant events 34 Climate targets, as filed Climate targets, as filed 1 Workforce and board diversity, as filed Workforce and board diversity, as filed 1

Rows recorded per section (log scale)

1 more section with rows · 15 sections measured, none recorded

This page covers Orchestra BioMed Holdings, Inc. and 3 companies grouped under it: 25 lead-sponsored trials (2 its own, 23 in the grouped companies) and 4 legal-entity registrations (1 its own, 3 in the grouped companies).

Get the Orchestra BioMed Holdings, Inc. report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Companies grouped under this page (3)

Shown in this order: most lead trials first.

Companies grouped under this page
Company Lead trials Legal entities
BackBeat Medical Inc. (United States) 12 1
Motus GI Medical Technologies Ltd 11 0
ACCELERATED TECHNOLOGIES PTY LTD 0 2

Disease areas (5)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Coronary Artery Disease 1
Coronary Disease 1
Essential Hypertension 1
Hypertension 1
Isolated Systolic Hypertension 1

Trials by start year as sponsor or collaborator (2)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials by start year as sponsor or collaborator
Year Trials started
2025 1
2023 1

No forecast is made for this organization: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

Journals published in (1)

Journals published in
Journal Publications
Journal of the American Heart Association 2

SEC-reported annual financials (6)

Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.

SEC-reported annual financials
Fiscal year Revenue (USD) Net income (USD) R&D (USD)
2025 33,482,000 -52,701,000 58,185,000
2024 2,638,000 -61,024,000 42,804,000
2023 2,760,000 -49,120,000 33,822,000
2022 3,533,000 -33,608,000 21,945,000
2021 not reported -378,753 not reported
2020 not reported not reported not reported

Financing and grant events (34)

Shown in this order: most recent first.

Financing and grant events
Date Round type Amount (USD) Source
2026-01-12 Other financing not disclosed Sec extracted
2025-11-21 Other financing not disclosed Edgar offerings
2025-10-24 Private placement not disclosed Sec extracted
2025-08-01 Other financing not disclosed Edgar offerings
2025-08-01 Public offering 40,000,000 Sec extracted

Showing 5 of 34 events.

Start your 14-day trial Email me all 34 events as a PDF

Climate targets, as filed (1)

Climate targets, as filed
Reporting year Net-zero target
2025 not disclosed

Workforce and board diversity, as filed (1)

Workforce and board diversity, as filed
Reporting year Workforce % women Board % women
2025 not disclosed not disclosed

Latest dated events (36)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-01-12 Financing Funding rounds and grants (NIH RePORTER + SEC EDGAR)
2025-11-21 Financing Funding rounds and grants (NIH RePORTER + SEC EDGAR)
2025-10-24 Private placement Funding rounds and grants (NIH RePORTER + SEC EDGAR)
2025-10-20 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-08-01 Financing Funding rounds and grants (NIH RePORTER + SEC EDGAR)

Showing 5 of 36 events.

Start your 14-day trial Email me all 36 events as a PDF

Not on this page

Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, approved assets, sponsor delivery record, us granted patents, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, organization relationships, clia clinical laboratory certificates, biomarker capability evidence, and biomarkers this organization publishes on.